|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 20, 2017 ) Global Alzheimer’s Disease Therapeutics and Diagnostics Market is projected to reach USD 12.43 billion by 2021, at a CAGR of 4.62% from 2016 to 2021.Alzheimer’s disease (AD) is the most regular cause of progressive dementia in the elderly populace. There has been an exponential increase in the frequency of Alzheimer’s disease cases globally, stressing the need to develop an effectual treatment to cure it. Marketed Drugs lead the global market on the basis of Therapeutics due to a large user base. Under Diagnostics segment, Computed tomography scan segment leads the global Alzheimer’s Disease Therapeutics and Diagnostics market. Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.
Presently, very few therapeutic options are present in the market and none of them offers a complete remedy for this condition. Hence, entry into the market would provide lucrative growth prospects to the industry players.
Get a comprehensive overview of the Global Alzheimer’s Disease Therapeutics and Diagnostics Market: http://www.marketdataforecast.com/market-reports/global-alzheimers-disease-therapeutics-and-diagnostics-market-2247/
Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Drivers & Restraints
The growth of the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is mainly driven by factors such as growing old age population, rising R&D investment, high frequency of Alzheimer’s and neurodegenerative diseases, and improved life expectancy of the general population. However, factors such as astronomical cost of treatment and lack of proper reimbursement policies are preventing the growth of the market.
Get accurate market forecast and analysis on the Alzheimer’s Disease Therapeutics and Diagnostics Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/global-alzheimers-disease-therapeutics-and-diagnostics-market-2247/request-sample
Global Alzheimer’s Disease Therapeutics and Diagnostics market segmentation
By Therapeutics
• Introduction
• Marketed Drugs
o NMDA Receptor Antagonists
o Cholinesterase Inhibitors
• Pipeline Drugs
• Y-o-Y Growth Analysis, By Therapeutics
• Market Attractiveness Analysis, By Therapeutics
• Market Share Analysis, By Therapeutics
By Diagnostics
• Introduction
• Computed tomography scan
• Electroencephalography
• Lumbar puncture test
• Magnetic resonance imaging
• Positron emission tomography
• Others
• Y-o-Y Growth Analysis, By Diagnostics
• Market Attractiveness Analysis, By Diagnostics
• Market Share Analysis, By Diagnostics
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at http://www.marketdataforecast.com/market-reports/global-alzheimers-disease-therapeutics-and-diagnostics-market-2247/customize-report
Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Overview
Alzheimer’s disease (AD) is the most regular cause of progressive dementia in the elderly populace. The imaging sector was worth $361 million in 2009 and is expected to increase at a nearly 19% compound annual growth rate (CAGR) to reach $852 million in 2014.Marketed Drugs lead the global market on the basis of Therapeutics due to a large user base. Under Diagnostics segment, Computed tomography scan segment leads the global Alzheimer’s Disease Therapeutics and Diagnostics market.
Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share. Overall, the forecast for Alzheimer's disease, including disease-modifying therapeutics, therapeutics that treat related symptoms, diagnostics and imaging, is set to increase exponentially. This market was worth $8 billion in 2009 and is expected to reach $9.6 billion by 2014, a compound annual growth rate (CAGR) of 3.7%. Diagnostics and biomarkers are expected to increase at a 5-year compound annual growth rate (CAGR) of nearly 20%. This segment was worth $1.2 billion in 2009 and is expected to reach $2.9 billion by 2014.
Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Region-wise Outlook
The market has also been geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa. North America is anticipated to be the largest market for Alzheimer’s disease Therapeutics and Diagnostics due to the growing prevalence of Alzheimer’s disease and extensive technological developments in the region. With the rise in aging populace in the developing region of Asia Pacific, this market is projected to grow at the highest CAGR during the forecast period.
Key Questions Answered
• What is the current and future Global Alzheimer’s Disease Therapeutics and Diagnostics Market outlook in global? What trends are affecting the global market?
• What is the competitive landscape and market share of major players in the Global Alzheimer’s Disease Therapeutics and Diagnostics space globally?
• What are the key, high growth markets that Global Alzheimer’s Disease Therapeutics and Diagnostics manufacturers should expand into? Which market segments are growing the fastest?
• What are the unmet needs with the Global Alzheimer’s Disease Therapeutics and Diagnostics currently on the market? How will emerging technologies fulfil these unmet needs?
• What is physician perception and market outlook of Alzheimer’s Disease Therapeutics and Diagnostics Market ?
• How is the Alzheimer's disease therapeutics and diagnostics market evolving?
• What is driving and restraining the Alzheimer's disease therapeutics and diagnostics market growth?
• What are the challenges and barriers that have hindered widespread adoption of Global Alzheimer’s Disease Therapeutics and Diagnostics Market?
• What are the key sustainability strategies adopted by market players ?
Global Alzheimer’s Disease Therapeutics and Diagnostics Market: Key Players
Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the global Alzheimer’s Disease Therapeutics and Diagnostics market are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialties with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
